

1 **Improving SARS-CoV-2 variants monitoring in the absence of**
2 **genomic surveillance capabilities: a serological study in Bolivian**
3 **blood donors in October 2021 and June 2022**

4
5 **Lucia Inchauste¹, Elif Nurtop¹, Lissete Bautista Machicado², Yanine Leigue Roth³,**
6 **Shirley Lenz Gonzales⁴, Maria Luisa Herrera⁵, Katty Mina Villafan⁶, Pedro Mamani**
7 **Mamani⁷, Marcelo Ramos Espinoza⁸, Juan Carlos Pavel Suarez⁹, Juan Cansio Garcia**
8 **Copa¹⁰, Yitzhak Leigue Zabala¹¹, Etzel Arancibia Cardozo¹², Pierre Gallian^{1,13}, Xavier**
9 **de Lamballerie¹ and Stéphane Priet^{1*}**

10

11 ¹ Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207),
12 Marseille, France

13 ² Programa Nacional de Sangre, Ministerio de Salud y Deportes, La Paz, Bolivia

14 ³ Banco de Sangre de Referencia Departmental de Beni, Beni, Bolivia

15 ⁴ Banco de Sangre de Referencia Departmental de Chuquisaca, Sucre, Bolivia

16 ⁵ Banco de Sangre de Referencia Departmental de Cochabamba, Cochabamba, Bolivia

17 ⁶ Banco de Sangre de Referencia Departmental de El Alto, El Alto, Bolivia

18 ⁷ Banco de Sangre de Referencia Departmental de La Paz, La Paz, Bolivia

19 ⁸ Banco de Sangre de Referencia Departmental de Oruro, Oruro, Bolivia

20 ⁹ Banco de Sangre de Referencia Departmental de Pando, Pando, Bolivia

21 ¹⁰ Banco de Sangre de Referencia Departmental de Potosí, Potosí, Bolivia

22 ¹¹ Banco de Sangre de Referencia Departmental de Santa Cruz, Santa Cruz, Bolivia

23 ¹² Banco de Sangre de Referencia Departmental de Tarija, Tarija, Bolivia

24 ¹³ Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS),
25 Marseille, France

26

27 * Correspondence: stephane.priet@univ-amu.fr; +33(0)4 13 73 21 51

28

29 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

30 **Abstract**

31 Unlike genomic data, serological data have not been previously leveraged to evaluate the
32 SARS-CoV-2 variants circulation. In Bolivia, sustained genomic surveillance capacities were
33 lacking especially at the beginning of the pandemic. In 2021 and 2022 we estimated the
34 prevalence of anti-SARS-CoV-2 antibodies in Bolivian blood donors and explored the
35 feasibility of using virus serum neutralization data for variants thought to have circulated to
36 map their circulation across all departments over a year-long follow-up period. Anti-S1 and
37 anti-NCP SARS-CoV-2 IgGs were studied, along with virus neutralization tests for ancestral-
38 D614G, Gamma, Delta, and Omicron BA.1 lineages of SARS-CoV-2. Between 2021 and 2022,
39 the overall prevalence of anti-S1 and anti-NCP antibodies increased reaching values over 90%,
40 demonstrating that a large proportion of the Bolivian population was no longer naïve to the
41 virus. Viral neutralization data, analyzed through multiple approaches, revealed the spread of
42 the Gamma variant up to 2021, particularly impacting northern departments. In 2022, Gamma
43 continued to circulate in southernmost departments of the country and the emergence of
44 Omicron BA.1 was detected. These trends align with publicly available genomic data from
45 neighboring countries. Our serological analyses successfully identified both new antigenic
46 groups, such as Omicron BA.1, and individual variants related to previously circulating groups,
47 such as Delta. The study contributes insights into overall population immunity to SARS-CoV-
48 2 and variant-specific immunity levels across different regions of Bolivia. It also emphasizes
49 the potency of seroprevalence studies in informing public health decisions and underscore their
50 value in capturing the initial phases of emerging epidemics when variant diversity is limited,
51 facilitating timely genomic surveillance setup.

52

53 **Keywords:** SARS-CoV-2 variants circulation, Infectious disease, Seroprevalence, Neutralizing
54 Antibodies, Public health, Latin America, SARS-CoV-2 surveillance, Decision making.

55

56 Introduction

57 Low- and middle-income countries in the Latin American region are vulnerable to health crises
58 due to a combination of factors such as poverty, fragile political and health systems, persistent
59 and pervasive inequality in income, health care, and education, among others¹. The SARS-
60 CoV-2 pandemic started in South America with the detection of the first case on February 26,
61 2020, at São Paulo, Brazil². Although it was initially thought that the pandemic would have less
62 of an impact on this region due to its younger population structure, the pandemic eventually
63 had a significant impact, accounting for 25% of infections worldwide³.

64 Seroprevalence studies are a valuable adjunct to active surveillance because they allow analysis
65 of the level of immunity of a population to a specific pathogen without the need for prospective
66 testing, and also provide information on the frequency of cases that do not attract medical
67 attention⁴. During the first years of the SARS-CoV-2 pandemic, a few South American
68 population-based seroprevalence studies were conducted in Colombia, Perú, Chile, and Brazil⁵-
69 ¹¹. Reported seroprevalence values varied through time and geographical location. Notably,
70 high prevalence was observed in locations such as Iquitos-Perú (70%) or Manaus-Brazil (54%)
71 after the first wave^{6,10}. However, an unexpected violent second wave occurred concomitantly
72 with the emergence of the Gamma variant, despite the high levels of seroprevalence reported
73 earlier¹⁰⁻¹². Despite the serious impact of COVID-19 on public health in Bolivia, research
74 studies are still lacking: one study reported a seroprevalence of 43.4% in January 2021 among
75 healthcare workers in the city of Cochabamba¹³, but no nationwide seroprevalence study is
76 currently available.

77 To date, the circulation of SARS-CoV-2 variants has mainly been studied through molecular
78 surveillance. However, in countries without significant genomic surveillance capabilities at the
79 start of the epidemic, it has become difficult to assess the spread and impact of variants. Here,
80 we have attempted to reconstruct parts of the history of the spread of SARS-CoV-2 in Bolivia
81 by studying the prevalence and specific neutralizing capacity of anti-SARS-CoV-2 antibodies
82 in blood donors from all Bolivian departments after the second and third COVID-19 waves.
83 Based on the results obtained, we discuss the potential contribution of seroprevalence and
84 seroneutralization studies of viral variants and their complementarity with viral genomics data
85 during the different phases of dissemination of a pathogen such as SARS-CoV-2.

86

87

88 **Methods**

89 **Background**

90 In Bolivia, the first case of SARS-CoV-2 was reported on March 10th, 2020, and to date
91 1 209 619 cases and 22 407 deaths have been reported¹⁴. As for the rest of South America,
92 Bolivia has experienced five waves of SARS-CoV-2 cases: the initial wave (May-September
93 2020), followed by a second (January-July 2021), a third (December 2021 to February 2022),
94 a fourth (June-August 2022) and the most recent (November 2022 to January 2023). Data on
95 variants circulating in each wave in South America is available in several free-access databases
96 (*e.g.*, the PAHO dashboard) but Bolivian genomic data are scarce and only few sequences have
97 been deposited¹⁵⁻¹⁷.

98 ***During the first wave***, COVID-19 cases in Bolivia neighboring countries were due to ancestral
99 and D614G SARS-CoV-2 strains (Supplementary Figure S1)¹⁵⁻¹⁷. ***During the second wave***,
100 Alpha, Gamma, Lambda and Mu variants were the main types identified, with variable
101 distribution among countries. In contrast to Europe, the Alpha variant was not the most
102 prevalent in any country of South America. Moreover, no specific wave was produced and no
103 associated increase in mortality was observed due to the circulation of the Delta variant. ***The***
104 ***start of the third wave***, as in the rest of the world, was concomitant with the emergence and
105 spread of the Omicron (BA.1) variant. ***The next two waves*** were mainly caused by the Omicron
106 variants BA.2/BA.5 and BQ.1/XBB, respectively.

107

108 **Specimens and ethical considerations**

109 Samples were collected from volunteer blood donors that agreed to participate in the study and
110 provided written consent. The study was approved by the ethics committee of the Dr. Mario
111 Ortíz Suárez hospital, Santa Cruz de la Sierra, Bolivia (N° FWA0002686) and by the National
112 Blood Program from the Ministry of Health and Sports of Bolivia. Sampling was conducted in
113 close collaboration with the National Blood Program and each Departmental Reference Blood
114 Bank. A first batch of 4238 serum samples was collected between August 26, and October 04,
115 2021. Samples were obtained from all Departmental Reference Blood Banks of Bolivia, which
116 included the cities of Beni (N=733), Chuquisaca (N=294), Cochabamba (N=500), La Paz
117 (N=500), El Alto(N=500), Oruro (N=500), Pando (N=414), Potosí (N=197), Santa Cruz
118 (N=600), Tarija (N=500). A second batch was collected between May 30 and June 23, 2022,

119 including a total of 1161 sera from the Departmental Reference Blood Banks of Cochabamba
120 (N=212), La Paz (N=264), Santa Cruz (N=186) and Tarija (N=499).

121

122 **Vaccination coverage**

123 Vaccination campaign against SARS-CoV-2 in Bolivia started on January 29, 2021¹⁸.
124 Following the SAGE recommendations, vaccination started for the healthcare workers, then
125 extended to the elderly, and people living with underlying health conditions and later expanded
126 to the general population. Vaccines distributed in Bolivia included the mRNA vaccines
127 Comirnaty (Pfizer-BioNTech) and mRNA-1273 (Moderna), the inactivated virus vaccines
128 CoronaVac (Sinovac Biotech, China) and BBIBP-CorV (Sinopharm, China), the (adeno)viral
129 vector vaccines Ad26.CoV2.S (Johnson & Johnson), Vaxzevria (AstraZeneca), and Sputnik V
130 (Gamaleya Research Institute of Epidemiology and Microbiology). Administration of a booster
131 dose was started on October 11, 2021¹⁹.

132 SARS-CoV-2 vaccination coverage was estimated for both sampling periods (October 27, 2021
133 and May 30, 2022) based on data reported by the Bolivian Ministry of Health and the Bolivian
134 National Institute of Statistics²⁰⁻²². To calculate vaccination coverage, the number of vaccine
135 doses administered by the Bolivian Ministry of Health was related (by department and
136 nationally) to the total eligible population according to the Bolivian National Institute of
137 Statistics. At the time of the first and second sampling periods, the eligible population included
138 individuals over 18 years of age and over 11 years of age, respectively.

139

140 **Immunoassays**

141 All serum samples were first screened using the commercial kit Anti-SARS-CoV-2 Quantivac
142 ELISA IgG (Euroimmun) according to manufacturer's recommendations to detect anti-Spike
143 S1 antibodies. Specimens with $BAU/mL < 25.6$, $25.6 \leq BAU/mL < 35.2$, and $BAU/mL \geq 35.2$ were
144 considered negative, equivocal and positive, respectively.

145 Samples were also tested for the presence of anti-NCP SARS-CoV-2 IgG using an in-house
146 qSAT assay, as described elsewhere²³. Briefly, the CTD domain of the SARS-CoV-2 N protein
147 (EVAg, ref: 100P-03957) was coupled to a MAGPLEX® magnetic microsphere (Luminex
148 Corporation) using the xMAP® Antibody Coupling Kit (Luminex Corporation) following
149 manufacturer's recommendations ($60 \text{ pmol}/10^6$ beads). The coupled beads were resuspended

150 and counted on a Countess™ II Automated Cell Counter (Thermo) to a final concentration of
151 2×10^6 beads/ml. Samples diluted in Wash Solution (Thermo) at 1/400 were incubated with
152 1,000 coupled beads per well for 1 h at room temperature in a plate shaker protected from light.
153 After two washes, the beads were incubated with R-Phycoerythrin AffiniPure F(ab')₂ Fragment
154 Goat Anti-Human IgG F(ab')₂ (Jackson ImmunoResearch) for 1 h at room temperature in a plate
155 shaker protected from light. After washing, antigen-antibody reactions were read on an
156 INTELLIFLEX® system (Luminex Corporation) and the results were expressed as median
157 fluorescence intensity (MFI). Cut-off values for each SARS-CoV-2 antigen for the S, RBD and
158 NCP were described elsewhere²³.

159 For virus Neutralization Tests (VNT), strains from the B.1 (Bav-Pat1/2020 strain [D614G]),
160 P.1 (SARS-CoV-2/2021/JP/TY7-503 strain [Gamma]), B.1.617.2 (SARS-CoV-
161 2/2021/FR/0610 strain [Delta]), and B.1.1.529 (UVE/SARS-CoV-2/2021/FR/1514 strain
162 [Omicron BA.1]) lineages of SARS-CoV-2 were used. Except for Bav-Pat1/2020 strain
163 (courtesy of Prof. Drosten, Berlin), all strains were provided by the European Virus Archive
164 (EVAg) repository (www.european-virus-archive.com). VNTs were performed for samples
165 with a positive or equivocal result in the anti-Spike S1 ELISA as previously described²⁴. Four
166 separate VNT assays were performed in duplicate with strains representative of the D614G,
167 Gamma, Delta, and Omicron BA.1 variants. Briefly, the test consisted in mixing 110µL of a
168 serially diluted (from 1/20 to 1/40960) patient serum sample (in DMEM with 1% of
169 penicillin/streptomycin, Non-Essential Amino Acids and Glutamine), with 110µL of a fixed
170 quantity of a given SARS-CoV-2 strain, to reach a final concentration of 0.5 TCID₅₀/µL of
171 plasma dilution. This mixture was incubated for 1 hour at 37°C. One hundred µL was then
172 transferred onto a confluent Vero E6 TMPRSS2+ cells monolayer and incubated at 37°C under
173 5% of CO₂. On day 5 post infection, dilutions showing a cytopathic effect (CPE) were
174 considered negative (no neutralization) and those without CPE were considered positive
175 (complete neutralization of the SARS-CoV2 inoculum). The neutralization titer referred to as
176 the highest serum dilution with a positive result. Specimens with a VNT titer ≥ 20 were
177 considered positive.

178

179 **SARS-CoV-2 seroprevalence**

180 Prevalence values for anti-S1 and anti-NCP antibodies, and for neutralizing antibodies (nAbs)
181 against the ancestral D614G (D614G), Gamma (γ), Delta (δ), and Omicron BA.1 (\omicron) variants

182 were calculated using the Prevalence package RStudio version R-4.0.3²⁵. Positive or negative
183 status for each sample and every variable was determined using the cut-offs described above.
184 For all variables, number of positive and negative results were used for prevalence computing.
185 Regarding nAbs, prevalence values for each variant (D614G, γ , δ , o) in each department and
186 nationwide were calculated using the regular seropositivity titer cut-off at 20 (samples with a
187 titer ≥ 20 were considered positive) and an alternative “high level” seropositivity titer cut-off at
188 ≥ 640 .

189

190 **Evaluation of the circulating variants using a "VNT Titers ratio method"**

191 The circulation of variants in Bolivia before October 2021 and June 2022 was first analyzed
192 through the distribution of samples exhibiting titers higher than the D614G ancestral strain for
193 a given variant of interest (γ , δ , o). The base 2 logarithm of VNT titer ratios (log₂-ratios) for
194 the following variants pairs was calculated: D614G/Gamma (D614G/ γ), D614G/Delta
195 (D614G/ δ), D614G/Omicron BA.1 (D614G/o). Negative log₂-ratio indicated that the variant in
196 the denominator (γ , δ , o) had a higher titer than D614. A log₂-ratio of 0 indicated that both
197 variants presented the same titer. To evaluate the circulation level of γ , δ , and o variants under
198 increasingly stringent conditions, we calculated the proportion of the population with log₂-ratio
199 values of ≤ 0 (variant titer equal to or greater than D614G), ≤ -1 (variant titer at least twice that
200 of D614G), and ≤ -2 (variant titer at least four times that of D614G) for each department.

201

202 **Quantification of the circulating variants according to antigenic groups**

203 Antigenic mapping of SARS-CoV-2 based on the neutralizing activity of each variant²⁶⁻²⁸
204 enables us to group the ancestral variants D614G, Alpha, Delta, Lambda, and Epsilon in one
205 group (GI), Beta, Gamma, Mu, Iota, and Zeta in a second group (GII), and Omicron and its
206 derivatives into a third group (GIII). To initiate the quantification of the variants circulating in
207 Bolivia, we initially employed a straightforward approach to estimate the percentage of samples
208 in each antigenic group within each department of Bolivia using two different methods (the
209 "Average titer method" and the "Variant assignment method").

210 *Average titer method*

211 To assess the neutralizing response across distinct antigenic groups, we used the average VNT
212 titer for the D614G and Delta variants to delineate antigenic group I (GI). Antigenic group II
213 (GII) was established based on the VNT titer for the Gamma variant, while antigenic group III
214 (GIII) was defined by the VNT titer for the Omicron BA.1 variant. For evaluating the
215 percentage of each antigenic group within different regions of Bolivia, GI was considered
216 dominant if its titer surpassed those of GII and GIII. Similarly, GII was considered if its titer
217 exceeded those of GI and GIII, and GIII was considered if its titer equaled or surpassed those
218 of GI and GII. Additionally, the prevalences of GI (from ancestral, Alpha, Delta, Lambda, and
219 Epsilon variants), the prevalences of GII (from Beta, Gamma, Mu, Iota, and Zeta variants), and
220 the prevalences of GIII (from all Omicron-derived variants) were obtained for neighboring
221 countries of Bolivia using publicly accessible genomic data when available.

222 *Variant assignment method*

223 **Assignment rules:** We implemented several rules taking into account the previously described
224 decrease in neutralizing activity of variants²⁶⁻²⁸ to determine which of the four variants tested
225 was expected to be responsible for the main or last infection (Supplementary Figure S2). Main
226 rules relied on D614G/ γ , D614G/ δ , and D614G/o log₂-ratios to differentiate between D614G,
227 Gamma, Delta, and Omicron variants. Given that Tarija had the lowest variant circulation level
228 and the highest vaccination coverage among the departments analyzed as October 2021, this
229 department was chosen as a reference for establishing the D614G cut-off values for the
230 subsequent rules defining the infection by γ , δ and o variants. Given that approximately 90% of
231 the population in this department exhibited D614G/ γ , D614G/ δ , and D614G/o log₂-ratios ≥ 0 ,
232 ≥ 0 , and ≥ 1 respectively, the D614G variant was assigned to compliant samples. If any of these
233 log₂-ratios fell below these threshold values, the corresponding variant (γ , δ , or o) was assigned.
234 Secondary rules were applied on a fraction of samples when the log₂-ratios for two pairs were
235 below the threshold values. Additional log₂-ratios for Delta/Gamma (δ/γ), Gamma/Omicron
236 BA.1 (γ/o) and Delta/Omicron BA.1 (δ/o) pairs were thus considered to differentiate between
237 the two variants. If both the D614G/ γ and D614G/ δ log₂-ratios were ≤ -1 , a δ/γ log₂-ratio ≤ 0
238 was chosen to indicate a Gamma infection, while a δ/γ log₂-ratio ≥ 1 indicated a Delta infection.
239 When the D614G/o log₂-ratio was ≤ 0 and the D614G/ γ log₂-ratio was also ≤ -1 , a γ/o log₂-
240 ratio ≥ 1 indicated a Gamma infection; otherwise (γ/o log₂-ratio ≤ 0) Omicron BA.1 was
241 assigned. Similarly, if the D614G/o log₂-ratio was ≤ 0 and the D614G/ δ log₂-ratio was ≤ -1 , a
242 δ/o log₂-ratio ≥ 1 suggested a Delta infection; otherwise (δ/o log₂-ratio ≤ 0) Omicron BA.1 was
243 assigned.

244 **Quantification according to assignment rules**: Variants assigned as D614G and Delta were
245 grouped in the antigenic group I, Gamma was set as the antigenic group II, and Omicron BA.1
246 as the antigenic group III. The percentage of samples in each antigenic group were calculated
247 for all departments for each sampling period.

248

249 **Quantification of the circulating variants according to individual variants**

250 The percentage of samples assigned through the Assignment Rules (*cf. supra*) to D614G,
251 Gamma, Delta or Omicron BA.1 was calculated for all departments for each sampling period.

252

253 **Results**

254 **Population studied**

255 A first sampling was carried out in blood donors from all Bolivian departments from August
256 26 to October 4, 2021, after the second epidemic wave (Supplementary Figure S1). A second
257 sampling to follow the evolution of the virus 6 months later was carried out in the 3 most
258 populated departments as well as in the most southern department (May 30 to June 23, 2022,
259 corresponding to the phase before the fourth wave).

260 Among the 4738 blood donors included for the first period, age ranged from 18 to 64 years,
261 with a median of 29 years (IQR, [23-37]). In the second period, 1161 blood donors were
262 included, ranging in age from 18 to 82 years, with a median of 32 years (IQR, [25-41]). There
263 was a balanced distribution of males (41.9% and 44.4%) and females (58.1% and 55.0%) for
264 both periods.

265

266 **Vaccination coverage**

267 Vaccination coverage data obtained from the Bolivian Ministry of Health are summarized in
268 Supplementary Figure S3 for both periods with respect to vaccination coverage for the first
269 dose, 2 doses and a booster (3 doses).

270 **In October 2021**, the vaccination coverage of the Bolivian population with a first dose ranged
271 from 47.6% (Potosí) to 70.3% (Tarija), reaching 59.3% at the national level. Coverage for the
272 complete vaccination schedule (referred as two doses) varied from 38.4% (Pando) to 61.4%
273 (Tarija), with a national average of 50.1%. The proportion of people who received one boost
274 was very low, ranging from 0% (Pando) to 4.5% (Cochabamba), with a national average of
275 3.2%.

276 **In May 2022**, the coverage for one dose increased significantly, ranging from 62.3% (Pando)
277 to 84.3% (Tarija), with a national average of 76.5%. Full vaccination coverage (2 doses)
278 reached 46.6% (Pando) to 72.9% (Tarija), or 63.8% nationally. The one boost coverage reached
279 16.2% nationwide (10.9% (Beni) to 22.4% (Tarija)). Compared to the first sampling period,
280 regions with higher (Tarija) and lower (Pando) vaccine coverage remained the same.

281

282 **Anti-SARS-CoV-2 Spike S1 and -NCP antibody prevalence**

283 The anti-SARS-CoV-2 Spike S1 (anti-S1) antibody levels were assessed in each department for
284 both sampling periods (Figure 1A and 1C).

285 In October 2021, at the national level, anti-S1 seroprevalence was 86.3% (95%CI: 85.3 – 87.6)
286 and varied from 77.2% (Beni) to 92.4% (Potosí). Seroprevalence increased to 97.1% (95%CI:
287 95.9–97.9) by June 2022, ranging from 96.6% (Tarija) to 98.5% (La Paz).

288 In October 2021, the anti-NCP seroprevalence was 60.8% (95%CI: 59.5 – 62.1) at a national
289 level, increasing to 90.2% (95%CI: 88.3 – 91.7) in June 2022 (Figures 1B and 1D).
290 In 2021, anti-NCP seroprevalence spanned from 52.7% (Pando) to 76.1% (Potosí). In 2022, the
291 range extended from 85.5% (Santa Cruz) to 92.8% (Tarija). The anti-NCP antibody prevalence
292 was always lower than anti-S1 antibody prevalence in October 2021 and June 2022. The anti-
293 NCP increase in the 4 regions tested was around 30%, while the anti-S1 increase was 8-13%.

294

295 **Prevalence of neutralizing antibodies.**

296 *Prevalence of nAbs against D614G*

297 **In October 2021**, the nationwide prevalence of D614G nAbs at cut-offs ≥ 20 and ≥ 640 were
298 83.1% and 29.1% (Figure 2 and Supplementary Figure S4), respectively, with a geometric mean
299 titer (GMT) of 159 (Supplementary Figure S5). The prevalence of D614G nAbs using the cut-
300 off ≥ 20 was consistently high across the entire country, ranging from 76.8% in Cochabamba to
301 90.3% in Potosí. Increasing the cut-off to ≥ 640 revealed that Pando and Tarija had the highest
302 (45.6%) and lowest (17.7%) prevalence, respectively. The rest of the country showed values
303 ranging between 21.5% and 34.9%.

304 **By June 2022**, D614G nAbs nationwide prevalence increased to 98.5% and 57.7% for the cut-
305 off ≥ 20 and ≥ 640 respectively, with a GMT of 556. Prevalence obtained with the cut-off ≥ 20
306 was high across all tested departments, nearly reaching saturation. Using the cut-off ≥ 640 , the
307 highest prevalence was observed in La Paz (73.2%) and the lowest in Tarija (42.9%).

308 *Prevalence of nAbs against Gamma*

309 **In October 2021**, the nationwide prevalence of Gamma nAbs at cut-offs ≥ 20 and ≥ 640 were
310 80.8% and 32.5% respectively, with a GMT of 208, showing a substantial circulation of
311 Gamma, as expected. The 3 northern departments (Pando, La Paz and Beni) had the highest
312 GMTs, varying between 310 and 352. The lowest and highest values were observed in Tarija

313 (63.7%) and Potosí (91.3%), respectively. Using the “high-level cut-off” (≥ 640), similar to
314 D614G, the highest prevalence was in Pando (48.1%), and the lowest in Tarija (13.0%).

315 **By June 2022**, the nationwide prevalence increased to 97.9% and 64.4% for the regular and
316 high-level cut-offs, respectively, with a GMT of 778. The prevalence for the regular cut-off was
317 above 96.5% across all tested departments. The highest and lowest prevalence values with the
318 high-level cut-off were observed in Cochabamba (68.5%), and La Paz (51.8%), respectively.

319 *Prevalence of nAbs against Delta*

320 **In October 2021**, despite expectations of low or no circulation of the Delta variant, we found
321 76.7% and 19.1% prevalence values at cut-offs ≥ 20 and ≥ 640 for Delta nAbs, respectively. This
322 reflects the high titers observed for D614G, as the result of cross-neutralization within antigenic
323 Group I. The Delta GMT was 81, compared to D614G (159) and Gamma (208).

324 **By June 2022**, the nationwide prevalence increased to 96.9% and 42.0% for the cut-offs ≥ 20
325 and ≥ 640 , respectively, with a GMT of 230. The prevalence obtained with the cut-off ≥ 20
326 exceeded 86.7% across all tested departments, and the highest and lowest prevalence values
327 with the cut-off ≥ 640 were found in La Paz (43.9%) and Santa Cruz (34.1%), respectively

328 *Prevalence of nAbs against Omicron BA.1*

329 **In October 2021**, prevalence for Omicron BA.1 was low (37.9% and 2.1% for the cut-off ≥ 20
330 and ≥ 640 , respectively), with a GMT of 23. In the absence of Omicron BA.1 circulation at this
331 time, this prevalence reflects cross-neutralization with D614G and Gamma.

332 **By June 2022**, nationwide prevalence increased to 90.7% and 19.9% for the cut-offs ≥ 20 and
333 ≥ 640 , respectively, with a GMT of 127. The highest prevalence at the cut-off ≥ 640 was recorded
334 in Tarija (21.1%), and the lowest in Santa Cruz (13.0%).

335

336 **Evaluation of the circulating variants**

337 This was performed using the “VNT Titers ratio method” (see Methods for details). Increasingly
338 stringent conditions (percentage of individuals in the population with titers of variants
339 equivalent to, twice or four times that of D614G) were tested (Figure 3 and Supplementary
340 Figure S6).

341 *Circulation of Gamma*

342 **In October 2021**, in the northern part of Bolivia, encompassing the Pando, La Paz, Beni, and
343 Cochabamba departments, the population exhibited the highest percentage of individuals with
344 Gamma titers superior to D614G. Conversely, Tarija (South) showed the lowest percentage.
345 This trend remained consistent across all conditions, including the most stringent ones.

346 **By June 2022**, the Gamma variant was more actively circulating in Tarija, Cochabamba, and
347 Santa Cruz. Compared to the first sampling period, this variant was less active in La Paz.

348 **We conclude that the gamma variant circulated mainly in the north of Bolivia before**
349 **October 2021, then spread to the southern regions of the country.**

350 *Circulation of Delta and Omicron BA.1*

351 **In October 2021**, evidence for the circulation of the Delta and Omicron BA.1 variants was
352 minimal, as expected (Supplementary Figure S1)¹⁵⁻¹⁷.

353 **By June 2022**, in contrast, the departments tested displayed an increase in the percentage of the
354 population with Delta and Omicron BA.1 titers superior to D614G. The highest values for both
355 Delta and Omicron BA.1 were found in Tarija and Cochabamba, and the lowest in La Paz and
356 Santa Cruz.

357 **We conclude that there is serological evidence for the circulation of both Delta and**
358 **Omicron BA.1 variants after October 2021.**

359

360 **Quantification of the circulating antigenic groups**

361 Using two approaches (the "Average titer method" and the "Variant assignment method"), the
362 circulating antigenic groups were quantified (Figure 4 and Supplementary Figure S7). The nAbs
363 responses resulting mainly from vaccination, ancestral, and Delta variants were clustered in
364 group I (GI), and Gamma and Omicron BA.1 were the representatives of groups II (GII) and
365 III (GIII), respectively. These two approaches yielded highly congruent results that were also
366 in agreement with the abovementioned results (Figure 3). Data from the "Average titer method"
367 was exposed in the following section (Figure 4).

368 *Antigenic Group I*

369 **In October 2021**, the percentages of GI-associated nAbs (GI-nAbs) spanned from 25.1%
370 (Cochabamba) to 80.9% (Tarija). The southernmost departments (Oruro, Potosí, and Tarija)

371 exhibited the highest values, aligning with genomic prevalence from surrounding countries for
372 which GI variants circulated more in Argentina (74.4%), Chile (57.4%) and Perú (79.4%).

373 **By June 2022**, the percentages of GI-nAbs extended from 30.2% (Tarija) to 79.3% (La Paz).
374 Compared to October 2021, the departments of La Paz and Cochabamba showed an increase in
375 the levels, while Santa Cruz and Tarija exhibited a decrease.

376 *Antigenic Group II*

377 **In October 2021**, the percentages of GII-associated nAbs (GII-nAbs) spanned from 19.1%
378 (Tarija) to 74.9% (Cochabamba). The northern departments (Pando, La Paz, Beni, and
379 Cochabamba) presented the highest levels, which reflects the circulation in neighboring Brazil
380 (80.5%).

381 **By June 2022**, the percentages of GII-associated nAbs (GII-nAbs) spanned from 16.5% (La
382 Paz) to 62.8% (Cochabamba). The southern departments of Santa Cruz and Tarija showed an
383 increase, while the northern departments of La Paz and Cochabamba showed a decrease in this
384 response.

385 *Antigenic Group III*

386 **In October 2021**, no evidence of circulation of GIII variants was observed from GIII-associated
387 nAbs (GIII-nAbs) in Bolivia, or genomic surveillance derived data from surrounding countries.

388 **By June 2022**, the percentages of GIII-nAbs varied from 1.7% (Santa Cruz) to 8.9% (Tarija).
389 GIII-nAbs increased across all tested departments, *i.e.* the method was capable of detecting the
390 emergence of the new antigenic group.

391 **We conclude that** these serological data nicely align with the circulation of each antigenic
392 group in the neighboring countries as computed from accessible genomic surveillance data,
393 particularly at the first sampling period (Figure 4 and Supplementary Figure S1).

394

395 **Quantification of the individual variant circulation**

396 The prevalence of individual variants, assigned through the Assignment Rules was examined
397 across all departments, showing similar trends with the above methods but offering a more
398 accurate assessment of ancestral and Delta variant circulation and possible insights into the

399 weight of vaccination in the generation of ancestral D614G-induced nAbs antibodies (Figure
400 S6 and S7).

401 *Quantification of ancestral D614G related variants circulation*

402 **In October 2021**, Tarija exhibited the highest D614G prevalence, while the northern
403 departments had some of the lowest circulation rates, a pattern consistent with vaccination
404 coverage data (Supplementary Figure S3) and the results observed above.

405 **By June 2022**, the southernmost departments of Santa Cruz, and Tarija, saw a reduction in
406 D614G prevalence. This trend comes with a higher level of Gamma circulation observed in
407 these two departments (see above), further supporting the hypothesis of ongoing Gamma
408 circulation between 2021 and 2022. In the department of Cochabamba, no significant change
409 in D614G prevalence was observed (28.3% in October 2020 to 26.6% in June 2022). In contrast,
410 La Paz experienced a notable surge (+40%) in D614G prevalence, consistently with the
411 antigenic group analysis.

412 *Quantification of Delta circulation*

413 **In October 2021**, a low circulation of Delta was observed in all departments, ranging from
414 1.1% (Pando) to 9.1%(Tarija). As a result, the method was able to detect the appearance of the
415 Delta variant, despite its belonging to the same antigenic group as other variants circulating
416 previously.

417 **By June 2022**, the prevalence of Delta remained stable or decrease across the tested
418 departments, with prevalences ranging between 1.5% (La Paz) and 9.1% (Tarija).

419

420

421 **Discussion**

422 To our knowledge, we are reporting the first serological study of SARS-CoV-2 to be carried
423 out in Bolivia in 2021 and 2022, which included blood donors from all the country's
424 departments. This study enabled us to estimate the level of immunity of the population to
425 SARS-CoV-2 nationwide and in the different regions of the country, thus providing valuable
426 information on the circulation of these variants in Bolivia.

427 Our study has limitations. Firstly, the study was limited to blood donors in the major cities of
428 Bolivia and may therefore not be fully representative of the populations of the country as a
429 whole. In addition, our results are based on serological data and may not be strictly identical to
430 the genomic data from a quantitative point of view, although they are likely to reflect similar
431 trends and distributions (see below).

432 *Epidemiological assessment*

433 As of October 2021, our data showed an anti-S1 SARS-CoV-2 seroprevalence of 86.3%,
434 indicating that a large part of the population had immunity against SARS-CoV-2 following
435 infection, vaccination, or both (Figure 1). Comparing the vaccination coverage with the anti-S1
436 antibody prevalence, we can infer that significant viral transmission occurred in the population
437 before October 2021 (Figure 1 and Supplementary Figure S3). These epidemiological data are
438 in agreement with other population-based studies performed on the first half of 2021 in Perú
439 and in the northwest of Brazil that reported high SARS-CoV-2 prevalence (63.6% and 65.0%,
440 respectively)^{6,10}. In Bolivia, the prevalence observed a few months later was even higher,
441 suggesting sustained virus circulation. By June 2022, although our sample was limited to four
442 departments, the data show a clear trend towards saturation in the prevalence of anti-S1,
443 suggesting that almost the entire population had been vaccinated and/or infected by that time.
444 With vaccination coverage having increased by around 13% (both for those who had received
445 two doses and those who had received the booster), the significant increase (+31.2%) in the
446 seroprevalence of anti-NCP antibodies indicates that a large proportion of the population has
447 been exposed to the virus between October 2021 and June 2022 (Figure 1). Even if a proportion
448 of newly vaccinated individuals had received an inactivated vaccine likely to generate an anti-
449 NCP response, this cannot explain the observed increase in the prevalence of anti-NCP
450 antibodies²⁹⁻³¹. This corresponds to the emergence of the Omicron BA.1 variant, which has
451 been shown to cause a high rate of infection worldwide^{32,33}.

452 Consistently, as of October 2021, the prevalence of nAbs against the ancestral D614G (83.1%)
453 and Gamma (80.8%) variants was very high throughout the country (Figure 2 and
454 Supplementary Figure S4). The 3 northern departments (Pando, La Paz and Beni) were the most
455 exposed to the Gamma variant, as reflected by the highest Gamma GMTs (Supplementary
456 Figure S5). By June 2022, the prevalence of neutralizing antibodies against all variants had
457 increased, reaching values higher than 90%, demonstrating that a large proportion of the
458 Bolivian population was no longer naïve to the virus.

459 When looking at nAbs with high neutralization titers, new variant circulation patterns emerged
460 (Figure 2 and Supplementary Figure S4). Some departments in the northern part of Bolivia,
461 especially Pando, may have suffered a greater impact during the two first waves, since nAbs
462 titers were higher for both the D614G and Gamma variants as of October 2021. To gain further
463 insight into the variant circulation, we proposed additional analyses ("VNT Titers ratio
464 method", "Average titer method", "Variant assignment method"; Figures 3 and 4 and
465 Supplementary Figures S6 to S8).

466 As of October 2021, a higher circulation of GII/Gamma was confirmed in northern Bolivia.
467 Moreover, it is likely that the first two waves had a significant impact on Pando, since (despite
468 having the lowest vaccine coverage in the country) high percentages of nAbs responses to the
469 ancestral D614G and Gamma variants were observed. On the other hand, the southernmost
470 department (Tarija) was probably the least affected, as it had the highest percentage of
471 neutralizing response to ancestral viruses and the lowest to Gamma, which is consistent with
472 its high vaccination coverage (the highest in the country). As for Delta, limited circulation was
473 observed across the country, corresponding to the beginning of its circulation in Latin America
474 (Supplementary Figure S1). As expected, no evidence of Omicron BA.1 was observed.

475 By June 2022, analyses showed that GII/Gamma continued to circulate in southernmost
476 departments (Cochabamba, Santa Cruz, and Tarija). Besides, the high level of nAbs against
477 GII/Gamma, observed in the first sampling period, in the population of La Paz seems to have
478 waned and in the contrary GI/D614G nAbs have risen (+40%). This observation cannot be
479 explained solely by an increase in vaccination coverage (Supplementary Figure S3), since
480 vaccination increased by only 13%. GI/D614G nAbs augmentation could be related to the
481 circulation of another GI variant, such as Lambda (which has circulated in the neighboring
482 country of Perú), or alternatively, the infection by the Delta and/or Omicron BA.1 variant may
483 have boosted the level of pre-existing anti-D614G nAbs in the population³⁴⁻³⁷. This boost of

484 pre-existing Abs phenomenon, known as antigenic sin, has been extensively documented in the
485 context of influenza infections and vaccinations^{38,39}. As for Delta, prevalences did not change
486 significantly, between October 2021 and June 2022, reflecting the limited Delta wave in Latin
487 America compared to Europe⁴⁰. Despite a significant global wave of the Omicron BA.1 variant
488 in South America, less than 9% of the Bolivian population tested displayed a neutralizing
489 antibody response against Omicron BA.1. This lower-than-expected nAbs response could be
490 attributed to the possibility that this variant increased the levels of pre-existing nAbs to previous
491 variants³⁴⁻³⁷.

492 *Significance of serological results*

493 To assess the significance and robustness of our serological results, we compared the results
494 obtained with the different methods used and with genomic data from neighboring countries.
495 We found that the patterns of circulation of antigenic groups/variants were consistent across the
496 different serological methods used (Figure 4 and Supplementary Figures S7 and S8) and that
497 they nicely aligned with the percentage of each antigenic group/variants in the neighboring
498 countries as computed from accessible genomic surveillance data (Supplementary Figure S1).

499 Serological analyses allowed detecting the emergence of a new antigenic group (*e.g.*, Omicron
500 BA.1), but also of an individual variant related to a previously circulating antigenic group (*e.g.*,
501 Delta). Overall, the accuracy of the mapping seems to have diminished with time, the number
502 of variants that have been circulated, vaccination and the saturation of prevalence estimates. As
503 an example, the prevalence values found for Omicron BA.1 in June 2022 are likely to be
504 underestimated (see Figure 4 and Supplementary Figures S1 and S8). Although the detection
505 of a new antigenic group remained possible in this specific study during the late period of
506 variants circulation, our results argue in favor of the greater usefulness of seroepidemiological
507 studies for documenting the early stages of a new epidemic. This is of great interest because it
508 gives time to set up genomic surveillance in countries with limited sequencing capacity at the
509 start of an epidemic emergence.

510

511 In conclusion, our study represents the first large-scale survey conducted in all the departments
512 of Bolivia, with a follow-up period of almost a year. This has enabled us to document ongoing
513 viral circulation and better characterize the epidemiology of SARS-CoV-2 in Latin America,
514 as well as providing essential information on the successive waves that have occurred in
515 Bolivia. In particular, despite a high prevalence in 2022, which could suggest the development

516 of herd immunity, subsequent waves demonstrate the virus ability to adapt and continue
517 circulating in a population that is no longer naïve. Our results confirm and reiterate that
518 seroprevalence studies are a powerful tool for informing public health decision-making. Our
519 findings strongly support the idea that seroepidemiological studies are valuable for capturing
520 the initial phases of a new epidemic, giving time for the establishment of genomic surveillance
521 in countries with limited sequencing capacity at the onset of an emerging epidemic.

522

523 **Conflict of Interest**

524 All the authors declare no competing interests.

525 **Funding Source**

526 This study was supported by the French National Research Institute for Sustainable
527 Development (IRD), the project EMERGEN-PRI #22275 of the ANRS I MIE (INSERM), and
528 the European Union's Horizon 2020 research and innovation program (European Virus Archive
529 Global, grant agreement No. 871029). The funders of the study had no role in study design,
530 data collection, data analysis, data interpretation, or writing of the report.

531 **Ethical Approval**

532 Samples were collected randomly from volunteer blood donors that agreed to participate in the
533 study. Written consent was obtained from all blood donors. The study was approved by the
534 ethics committee of the Dr. Mario Ortíz Suárez hospital, Santa Cruz de la Sierra, Bolivia (N°
535 FWA0002686) and by the National Blood Program from the Ministry of Health and Sports of
536 Bolivia. Sampling was carefully conducted in close collaboration with the National Blood
537 Program and each Departmental Reference Blood Bank.

538 **Authors Contributions**

539 LI, XdL, and SP conceived the study design. LBM, LI, RFZ, SLG, MLH, MLP, VT, RVFF,
540 JCPS, PAO, YLZ, and EAC coordinated and managed sampling. LI and EN performed the
541 serological assays. LI and SP performed the data curation. LI, XdL, and SP prepared the draft
542 of the manuscript. All the authors have reviewed, contributed and approved the final
543 manuscript.

544 **Acknowledgments**

545 The authors thank all professionals from the Departmental Reference Blood Banks. A special
546 thanks to Dra. Daniela Azurduy, Dra. Vanessa Telleria, Dra. Cecilia Peralta, Dra. Rosario
547 Quintanilla, Dra. Rosa Escalier, Dra. Patricia Achacollo Olmo, Dra. Raquel Verónica Figueredo
548 Flores, Dr. Ronald Flores Zabala, and Dra. Maria Luisa Patón for their support and management
549 to carry out the sampling for the project. We would also like to thank the collaboration of the
550 Ministerio de Salud y Deportes, the Viceministerio de Gestión del Sistema de Salud and the
551 Dirección de Redes de Servicios de Salud.

552

553 **References**

- 554 1. The L. COVID-19 in Latin America: a humanitarian crisis. *The Lancet* 2020; **396**(10261): 1463.
- 555 2. Melo CML, Silva GAS, Melo ARS, Freitas AC. COVID-19 pandemic outbreak: the Brazilian reality
556 from the first case to the collapse of health services. *Anais da Academia Brasileira de Ciências* 2020;
557 **92**(4): e20200709.
- 558 3. The L. COVID-19 in Latin America-emergency and opportunity. *Lancet (London, England)* 2021;
559 **398**(10295): 93.
- 560 4. Wu KM, Riley S. Simulation-guided design of serological surveys of the cumulative incidence of
561 influenza infection. *BMC infectious diseases* 2014; **14**: 505.
- 562 5. Reyes-Vega MF, Soto-Cabezas MG, Cárdenas F, et al. SARS-CoV-2 prevalence associated to low
563 socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological
564 survey in Lima, Peru. *EClinicalMedicine* 2021; **34**: 100801.
- 565 6. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, et al. Seroprevalence of anti-SARS-CoV-2
566 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. *The Lancet Global
567 Health* 2021; **9**(7): e925-e31.
- 568 7. Vial P, González C, Icaza G, et al. Seroprevalence, spatial distribution, and social determinants
569 of SARS-CoV-2 in three urban centers of Chile. *BMC infectious diseases* 2022; **22**(1): 99.
- 570 8. Mercado-Reyes M, Malagón-Rojas J, Rodríguez-Barraquer I, et al. Seroprevalence of anti-SARS-
571 CoV-2 antibodies in Colombia, 2020: A population-based study. *The Lancet Regional Health – Americas*
572 2022; **9**.
- 573 9. Nicolete VC, Rodrigues PT, Fernandes ARJ, et al. Epidemiology of COVID-19 after Emergence of
574 SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020-2021. *Emerging infectious diseases* 2022; **28**(3):
575 709-12.
- 576 10. Buss LF, Prete CA, Jr., Abraham CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the
577 Brazilian Amazon during a largely unmitigated epidemic. *Science (New York, NY)* 2021; **371**(6526): 288-
578 92.
- 579 11. Prete CA, Buss LF, Buccheri R, et al. Reinfection by the SARS-CoV-2 Gamma variant in blood
580 donors in Manaus, Brazil. *BMC infectious diseases* 2022; **22**(1): 127.
- 581 12. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite
582 high seroprevalence. *The Lancet* 2021; **397**(10273): 452-5.
- 583 13. Saba Villarroel PM, Castro Soto MdR, Undurraga V, et al. High SARS-CoV-2 Prevalence among
584 Healthcare Workers in Cochabamba, Bolivia. *Viruses* 2022; **14**(2): 232.
- 585 14. WHO. WHO Coronavirus (COVID-19) Dashboard. 2023. <https://covid19.who.int/> (accessed
586 13/11/2023).
- 587 15. PAHO. SARS-CoV-2 Variants Tracking in the Region of the Americas. 2023.
588 https://ais.paho.org/phis/viz/SARS_CoV2_variants_regional.asp (accessed 13/04/2023).

- 589 16. GISAID. Phylodynamics of pandemic coronavirus in Latin America and the Caribbean.
590 11/04/2023 2023. [https://phyldynamics.pandemicpreparedness.org/dist/start.html?id=TGF0aW4lMjBBbWVyaWNh&s=](https://phyldynamics.pandemicpreparedness.org/dist/start.html?id=TGF0aW4lMjBBbWVyaWNh&s=1&h=0)
591 [1&h=0](https://phyldynamics.pandemicpreparedness.org/dist/start.html?id=TGF0aW4lMjBBbWVyaWNh&s=1&h=0) (accessed 13/04/2023).
592
593 17. Hodcroft E. CoVariants. 12/04/2023 2023. <https://covariants.org/> (accessed 13/04/2023).
594 18. Bolivia MdSyDd. Inicia El Proceso de Vacunación Al Personal de Salud Que Lucha en Primera
595 Línea Contra la Pandemia. 2021. <https://www.minsalud.gob.bo/5230-inicia-proceso-vacunacion>
596 (accessed 17/04/2023).
597 19. Bolivia MdSyDd. Salud Dispone 800.000 Vacunas Para Inmunizar Con Dosis Adicional A
598 Mayores De 60 Años Y Con Patologías De Base. 2021. [https://www.minsalud.gob.bo/6104-salud-](https://www.minsalud.gob.bo/6104-salud-dispone-800-000-vacunas-para-inmunizar-con-dosis-adicional-a-mayores-de-60-anos-y-con-patologias-de-base)
599 [dispone-800-000-vacunas-para-inmunizar-con-dosis-adicional-a-mayores-de-60-anos-y-con-](https://www.minsalud.gob.bo/6104-salud-dispone-800-000-vacunas-para-inmunizar-con-dosis-adicional-a-mayores-de-60-anos-y-con-patologias-de-base)
600 [patologias-de-base](https://www.minsalud.gob.bo/6104-salud-dispone-800-000-vacunas-para-inmunizar-con-dosis-adicional-a-mayores-de-60-anos-y-con-patologias-de-base) (accessed 02/05/2023).
601 20. Bolivia MdSyDd. Reporte de Vacunacion Contra la COVID-19 al 30 de Mayo de 2022. 2022.
602 [https://www.minsalud.gob.bo/6729-covid-19-salud-informa-que-esta-jornada-se-aplicaron-10-393-](https://www.minsalud.gob.bo/6729-covid-19-salud-informa-que-esta-jornada-se-aplicaron-10-393-dosis-en-el-pais-y-casos-positivos-llegan-a-203)
603 [dosis-en-el-pais-y-casos-positivos-llegan-a-203](https://www.minsalud.gob.bo/6729-covid-19-salud-informa-que-esta-jornada-se-aplicaron-10-393-dosis-en-el-pais-y-casos-positivos-llegan-a-203) (accessed 02/05/2023).
604 21. Bolivia MdSyDd. Reporte de vacunacion contra la COVID-19 al 27 de octubre 2021. 2021.
605 [https://www.minsalud.gob.bo/6163-covid-19-hasta-hoy-la-inmunizacion-alcanza-a-7-650-594-](https://www.minsalud.gob.bo/6163-covid-19-hasta-hoy-la-inmunizacion-alcanza-a-7-650-594-vacunas-aplicadas-con-primeras-segundas-unidosis-y-tercera-dosis)
606 [vacunas-aplicadas-con-primeras-segundas-unidosis-y-tercera-dosis](https://www.minsalud.gob.bo/6163-covid-19-hasta-hoy-la-inmunizacion-alcanza-a-7-650-594-vacunas-aplicadas-con-primeras-segundas-unidosis-y-tercera-dosis) (accessed 02/05/2023).
607 22. INE. Población Y Hechos Vitales; Proyecciones de Población, Revisión 2020. 2023.
608 <https://www.ine.gob.bo/index.php/censos-y-proyecciones-de-poblacion-sociales/> (accessed
609 02/05/2023).
610 23. Inchauste L, Nurtop E, Brisbarre N, Gallian P, de Lamballerie X, Priet S. Exploring cell-free assays
611 for COVID-19 serosurvey. *Submitted* 2023.
612 24. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of
613 antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral research* 2020; **181**:
614 104880.
615 25. Devleeschauwer B, Torgerson P, Charlier J, et al. Package ‘prevalence’. 2013.
616 26. Mykytyn AZ, Rissmann M, Kok A, et al. Antigenic cartography of SARS-CoV-2 reveals that
617 Omicron BA.1 and BA.2 are antigenically distinct. *Sci Immunol* 2022; **7**(75): eabq4450.
618 27. Wilks SH, Muhlemann B, Shen X, et al. Mapping SARS-CoV-2 antigenic relationships and
619 serological responses. *Science (New York, NY)* 2023; **382**(6666): eadj0070.
620 28. van der Straten K, Guerra D, van Gils MJ, et al. Antigenic cartography using sera from sequence-
621 confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron.
622 *Immunity* 2022; **55**(9): 1725-31 e4.
623 29. Muená NA, García-Salum T, Pardo-Roa C, et al. Induction of SARS-CoV-2 neutralizing antibodies
624 by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals. *eBioMedicine*
625 2022; **78**.
626 30. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2.
627 *Science (New York, NY)* 2020; **369**(6499): 77-81.
628 31. Dashdorj NJ, Wirz OF, Roltgen K, et al. Direct comparison of antibody responses to four SARS-
629 CoV-2 vaccines in Mongolia. *Cell Host Microbe* 2021; **29**(12): 1738-43 e4.
630 32. Silva SJRd, Kohl A, Pena L, Pardee K. Recent insights into SARS-CoV-2 omicron variant. 2023;
631 **33**(1): e2373.
632 33. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
633 *Lancet (London, England)* 2021; **398**(10317): 2126-8.
634 34. Quandt J, Muik A, Salisch N, et al. Omicron BA.1 breakthrough infection drives cross-variant
635 neutralization and memory B cell formation against conserved epitopes. *Sci Immunol* 2022; **7**(75):
636 eabq2427.
637 35. Kaku CI, Bergeron AJ, Ahlm C, et al. Recall of preexisting cross-reactive B cell memory after
638 Omicron BA.1 breakthrough infection. *Sci Immunol* 2022; **7**(73): eabq3511.
639 36. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing
640 antibodies elicited by SARS-CoV-2 infection. *Science (New York, NY)* 2021; **372**(6549): 1413-8.

- 641 37. Gallian P, Brisbarre N, Nurtop E, et al. Low neutralization capacity against SARS-CoV-2 Omicron
642 BQ.1.1 of convalescent plasma collected during circulation of Omicron BA.1. *Vox Sang* 2023; **118**(5):
643 407-8.
- 644 38. Viboud C, Epstein SL. First flu is forever. *Science (New York, NY)* 2016; **354**(6313): 706-7.
- 645 39. Monto AS, Malosh RE, Petrie JG, Martin ET. The Doctrine of Original Antigenic Sin: Separating
646 Good From Evil. *J Infect Dis* 2017; **215**(12): 1782-8.
- 647 40. Giovanetti M, Fonseca V, Wilkinson E, et al. Replacement of the Gamma by the Delta variant
648 in Brazil: Impact of lineage displacement on the ongoing pandemic. *Virus Evol* 2022; **8**(1): veac024.
- 649




Figure 1: Prevalence of anti-SARS-CoV-2 Spike S1 and -NCP antibodies in Bolivia as October 2021 and June 2022.

The prevalence of anti-SARS-CoV-2 Spike S1 (A, C) and -NCP (B, D) antibodies was reported for each department in Bolivia and nationwide as October 2021 (A, B) and June 2022 (C, D).




Figure 2: Prevalence of neutralizing anti-SARS-CoV-2 antibodies in Bolivia as October 2021 and June 2022.

The prevalence of neutralizing antibodies was reported for each department in Bolivia and nationwide for the D614G (A, E), Gamma (B, F), Delta (C, G) and Omicron BA.1 (D, H) variants as October 2021 (upper panel: A, B, C, D) and June 2022 (lower panel: E, F, G, H). The prevalence was obtained with the positivity cut-off ≥ 640 .




Figure 3: Variant circulation in Bolivia as October 2021 and June 2022.

Percentage of the population exhibiting titers for Gamma, Delta, and Omicron BA.1 being at least equivalent to ($\log_2\text{-ratios} \leq 0$, upper panel: A, B, C, D), twice ($\log_2\text{-ratios} \leq -1$, middle panel: E, F, G, H), or four times ($\log_2\text{-ratios} \leq -2$, lower panel: I, J, K, L) that of D614G are presented for each department of Bolivia. Results for D614G/γ are depicted in blue as October 2021 (A, E, I) and June 2022 (B, F, J). Results obtained as June 2022 for D614G/δ and for D614G/o are depicted in green (C, G, K) and in red (D, H, L), respectively. D614G: ancestral D614G variant; γ: Gamma variant; δ: Delta variant; o: Omicron BA.1 variant.

As October 2021

As June 2022




Figure 4: Quantification of SARS-CoV-2 circulating antigenic groups in Bolivia by Average titer method as October 2021 and as June 2022.

Percentage of the population in each department presenting a neutralizing antibody response against a defined antigenic group, including the GI (green), GII (blue), GIII (red), using the Average titer method.

For antigenic group assignment by VNT, D614G and Delta variants were cluster in to the antigenic group I (GI), antigenic group II (GII) corresponded to the Gamma variant, while antigenic group III (GIII) was defined by the Omicron BA.1 variant (see methods for details). For evaluating genomic data, the prevalences of GI (from ancestral, Alpha, Delta, Lambda, and Epsilon variants; light-green), the prevalences of GII (from Beta, Gamma, Mu, Iota, and Zeta variants; light-blue), and the prevalences of GIII (from all Omicron-derived variants; light-red) were obtained for neighboring countries of Bolivia using publicly accessible genomic data when available.